← Issue №16/ week of Oct 18, 2026/Nutrition

A health-system-scale, episode-resolved multimodal atlas of cancer cachexia.

From GI Signals issue №16: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Nutrition prospective cohort · n=52,236 · Oct 12, 2026 · Nature Medicine · IF 52.5

A health-system-scale, episode-resolved multimodal atlas of cancer cachexia.

Basic sciencebasic sciencetranslationalbiomarkerepidemiology
Clinical takeawayNo clinical action yet: this study identifies biomarkers and tumor genotypes associated with cancer cachexia but does not propose a specific intervention or treatment.
What it foundCachectic episodes clustered near disease progression and were associated with inferior outcomes across nearly all cancer types, with a serologic signature of lower albumin and hemoglobin and higher liver enzymes.
ContextThis study refines understanding of cancer cachexia by linking it to specific serologic markers and tumor genotypes, building on prior evidence of its association with poor outcomes.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Castillon VJ … Reznik E · Nature Medicine · IF 52.5 · PubMed ↗Permalink
← Read the whole of issue №16 Every paper GI Signals surfaces gets a page like this one. All issues